Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

【导读】肝细胞癌（HCC）的特点是经常发生肝内和远处转移，导致患者预后差。11月12日，安徽医科大学与南京医科大学研究人员合作共同在期刊《Advanced Science》上发表了题为“NSUN5 Facilitates Hepatocellular ...

在这项最新研究中，研究团队发现，尽管癌周CTL表现出具有克隆扩增和高反应性的CD103 + 组织驻留效应表型，但这些细胞的聚集预示着接受手术切除、ICB疗法、手术切除+ICB疗法，以及ICB疗法+经动脉灌注化疗的患者的不良治疗结局。

Liver biomarkers at baseline in addition to changes during follow-up are associated with cirrhosis and HCC in HDV.

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data ...

Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular ...

Application error: a client-side exception has occurred (see the browser console for more information).